Lipika Goyal

18.4k total citations · 6 hit papers
185 papers, 5.1k citations indexed

About

Lipika Goyal is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Lipika Goyal has authored 185 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 97 papers in Surgery and 72 papers in Molecular Biology. Recurrent topics in Lipika Goyal's work include Cholangiocarcinoma and Gallbladder Cancer Studies (90 papers), Fibroblast Growth Factor Research (54 papers) and Pancreatic and Hepatic Oncology Research (49 papers). Lipika Goyal is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (90 papers), Fibroblast Growth Factor Research (54 papers) and Pancreatic and Hepatic Oncology Research (49 papers). Lipika Goyal collaborates with scholars based in United States, United Kingdom and Spain. Lipika Goyal's co-authors include Andrew X. Zhu, Ángela Lamarca, Juan W. Valle, Mandar D. Muzumdar, Jorge Barriuso, John Bridgewater, Tim F. Greten, Robin Kate Kelley, Dan G. Duda and Funda Meric‐Bernstam and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Lipika Goyal

176 papers receiving 5.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

2023 740 citations Lipika Goyal et al. profile →
New Horizons for Precision Medicine in Biliary Tract Cancers

2017 425 citations Juan W. Valle, Lipika Goyal et al. Cancer Discovery profile →
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma

2018 362 citations Andrew X. Zhu, Lipika Goyal et al. profile →
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

2021 171 citations Funda Meric‐Bernstam, Rastislav Bahleda et al. Cancer Discovery profile →
Immunology and immunotherapy of cholangiocarcinoma

2023 102 citations Nabeel Bardeesy, Lipika Goyal et al. profile →
Cholangiocarcinoma — novel biological insights and therapeutic strategies

2023 94 citations Lipika Goyal et al. profile →

Peers

Countries citing papers authored by Lipika Goyal

Since Specialization

Citations

This map shows the geographic impact of Lipika Goyal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lipika Goyal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lipika Goyal more than expected).

Fields of papers citing papers by Lipika Goyal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lipika Goyal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lipika Goyal. The network helps show where Lipika Goyal may publish in the future.

Co-authorship network of co-authors of Lipika Goyal

This figure shows the co-authorship network connecting the top 25 collaborators of Lipika Goyal. A scholar is included among the top collaborators of Lipika Goyal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lipika Goyal. Lipika Goyal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials 2025 ·Cancer ·(unknown), (unknown), Lianchun Xiao, Mitesh J. Borad, Robin Kate Kelley, Lipika Goyal, Nilofer S. Azad, Melinda Bachini, (unknown), Shubham Pant, Juan W. Valle, Lola A. Fashoyin‐Aje, Milind Javle	0
2	CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Alexander G. Raufi, Lipika Goyal, Elizabeth Smyth, Philip Szekeres, Marcella Petrone, (unknown), Kenneth S. Thress, (unknown), (unknown), (unknown), Rakesh Kumar, (unknown), Laura Barker, Yelena Y. Janjigian, Kohei Shitara	3
3	Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients 2024 ·Clinical Cancer Research ·Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, Do‐Youn Oh, John Bridgewater, (unknown), (unknown), (unknown), Volker Wacheck, Lipika Goyal	8
4	Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma—a real-world, multicenter study 2024 ·Therapeutic Advances in Medical Oncology ·Michael Li, Lindsay M. Hannan, Lipika Goyal, Andrea Grace Bocobo, Anna L. Parks, (unknown), Islam Baiev, (unknown), John D. Gordan, Alan P. Venook, (unknown), Paige M. Bracci, Robin Kate Kelley	1
5	Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling 2024 ·Annals of Oncology ·Lipika Goyal, Daniel DiToro, Antoine Hollebecque, John Bridgewater, (unknown), Arihiro Kano, (unknown), Jennifer L. Silhavy, Volker Wacheck, Abdel‐Baset Halim, Funda Meric‐Bernstam	2
6	Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology? 2024 ·JCO Precision Oncology ·Haley Ellis, Lipika Goyal	5
7	Germline Determinants of Esophageal Adenocarcinoma 2023 ·Gastroenterology ·(unknown), George Eng, (unknown), (unknown), (unknown), Rachid Zagani, Martin S. Taylor, Steffen Rickelt, Dmitriy Kedrin, (unknown), Ardeshir Z. Hashmi, Norman S. Nishioka, Chin Hur, Lipika Goyal, Fateh Bazerbachi, Lawrence Zukerberg, V.S. Deshpande, Ömer Yılmaz, Manish Gala	3
8	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Ronan J. Kelly, Katherine M. Bever, Joseph Chao, Kristen K. Ciombor, Cathy Eng, Marwan Fakih, Lipika Goyal, Joleen M. Hubbard, Renuka Iyer, Holly Kemberling, Smitha Krishnamurthi, Geoffrey Y. Ku, (unknown), Van K. Morris, Andrew Scott Paulson, (unknown), Manish A. Shah, Dung T. Le	14
9	Abstract LB012: Claudin-1 is a driver and therapeutic target for cholangiocarcinoma 2023 ·Cancer Research ·Marion Müller, Zeina Nehme, Émilie Crouchet, Frank Jühling, (unknown), Patrick Pessaux, Emanuele Felli, Lipika Goyal, Markus R. Meyer, Roberto Iacone, Alberto Toso, Luigi Manenti, Patrice Laquerrière, Aïna Venkatasamy, Nabeel Bardeesy, Catherine Schuster, Laurent Mailly, Thomas F. Baumert	0
10	An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma 2022 ·The Oncologist ·David C. Madoff, Nadine Abi‐Jaoudeh, (unknown), Lipika Goyal, Dhanpat Jain, Bruno C. Odisio, Riad Salem, Mark Schattner, Rahul A. Sheth, Daneng Li	9
11	FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures 2022 ·Clinical Cancer Research ·Vishwajith Sridharan, Azfar Neyaz, (unknown), Islam Baiev, Stephanie Reyes, Emily G. Barr Fritcher, Jochen K. Lennerz, William R. Sukov, Benjamin R. Kipp, David T. Ting, Vikram Deshpande, Lipika Goyal	9
12	Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study breakdown → 2021 ·Cancer Discovery ·Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik‐Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal	171
13	Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency 2020 ·Cancer Research ·Chi Luo, Jiaxin Liang, Kfir Sharabi, Maximilian Hatting, Elizabeth A. Perry, Clint D.J. Tavares, Lipika Goyal, Amitabh Srivastava, Marc Bilodeau, Andrew X. Zhu, Piotr Siciński, Pere Puigserver	16
14	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer 2020 ·Clinical Cancer Research ·Lipika Goyal, Cynthia A. Sirard, Michael Schrag, Michael H. Kagey, Jennifer R. Eads, Stacey Stein, Anthony B. El-Khoueiry, Gulam A. Manji, Thomas A. Abrams, Alok A. Khorana, Rebecca A. Miksad, Devalingam Mahalingam, Andrew X. Zhu, Dan G. Duda	46
15	The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients 2020 ·The Oncologist ·Ioannis A. Ziogas, (unknown), Dimitrios Giannis, (unknown), Konstantinos S. Mylonas, Samer Tohme, David A. Geller, Nahel Elias, Lipika Goyal, Georgios Tsoulfas	37
16	Targets for therapy in biliary tract cancers: the new horizon of personalized medicine 2020 ·Chinese Clinical Oncology ·(unknown), Ming‐Huang Chen, Lipika Goyal, Crystal S. Denlinger	5
17	Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers 2020 ·Cancer ·Areej El‐Jawahri, Lara Traeger, Joseph A. Greer, (unknown), (unknown), Barbara J. Cashavelly, (unknown), Ryan David Nipp, Kerry L. Reynolds, Lipika Goyal, Sunil Bhatt, Sarah Fishman, Nora Horick, Zhigang Li, Angelo E. Volandes, Jennifer S. Temel	5
18	Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma 2019 ·Journal of Clinical Pathology ·Diane Brackett, Azfar Neyaz, Kshitij S. Arora, Ricard Masia, Anthony R. Mattia, (unknown), Joseph Misdraji, Lipika Goyal, Andrew X. Zhu, Cristina R. Ferrone, Ömer Yılmaz, (unknown)	15
19	Phase I dose-escalation study of TAS-120, a highly selective, covalently bound FGFR inhibitor, in patients with advanced solid tumors 2018 ·Clinical Trials ·Rastislav Bahleda, Funda Meric‐Bernstam, Lipika Goyal, Ben Tran, Helen He, Robert Winkler, Cinta Hierro, Hendrik‐Tobias Arkenau	1
20	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma 2015 ·Clinical Cancer Research ·Francesco Sabbatino, Vincenzo Villani, Jennifer H. Yearley, Vikram Deshpande, Lei Cai, Ioannis T. Konstantinidis, Christina Moon, Sjoerd Nota, Yangyang Wang, Ahmad Al-Sukaini, Andrew X. Zhu, Lipika Goyal, David T. Ting, Nabeel Bardeesy, Theodore S. Hong, Carlos Fernández‐del Castillo, Kenneth K. Tanabe, Keith D. Lillemoe, Soldano Ferrone, Cristina R. Ferrone	162

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact